FIELD: chemistry.
SUBSTANCE: present invention relates to a method for synthesis of a radionuclide complex formed by a radionuclide and a peptide which binds a somatostatin receptor coupled with a chelating agent. Proposed method includes the following steps in the following order: a) introduction of the radionuclide precursor solution into the first vessel, b) transfer of the radionuclide precursor solution into the reactor, c) adding a working buffer solution into said first vessel containing a residual solution of the radionuclide precursor, d) transfer of working buffer solution and residual solution of radionuclide precursor from said first vessel into reactor, e) transferring a solution containing a peptide binding a somatostatin receptor coupled to a chelating agent into a reactor, f) reacting a peptide binding a somatostatin receptor coupled to a chelating agent with said radionuclide in a reactor to obtain a radionuclide complex, g) extraction of said radionuclide complex, where pH at step f) is between 3.0 and 7.0, and temperature at reaction step f) is in range of 80–100 °C.
EFFECT: invention provides high labelling output correlating with high radiochemical purity, high labelling output with minimum level of free (non-complexed) radionuclide, production of large number of doses in single batches.
24 cl, 6 dwg, 8 tbl, 2 ex
Title | Year | Author | Number |
---|---|---|---|
STABLE CONCENTRATED SOLUTIONS OF RADIONUCLIDE COMPLEXES | 2018 |
|
RU2789366C2 |
CYCLIC OCTAPEPTIDE, RADIOPHARMACEUTICAL AGENT BASED THEREON AND METHOD OF USING RADIOPHARMACEUTICAL AGENT TO PRODUCE MEDICINAL (PHARMACEUTICAL) AGENTS FOR TREATING NEOPLASMS EXPRESSING SOMATOSTATIN RECEPTORS | 2013 |
|
RU2528414C1 |
GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2693465C2 |
GRPR ANTAGONISTS FOR DETECTING, DIAGNOSING AND TREATING GRPR-POSITIVE ONCOLOGICAL DISEASE | 2013 |
|
RU2821944C2 |
PARAMINOHYPURIC ACID (PAH) AS A KIDNEY PROTECTOR | 2020 |
|
RU2804349C2 |
LYOPHILISATE BASED ON PROSTATE-SPECIFIC MEMBRANE ANTIGEN (PSMA) LIGANDS FOR PREPARING A RADIOPHARMACEUTICAL COMPOSITION IN FORM OF SOLUTION FOR INJECTIONS FOR TREATING PROSTATE CANCER, RADIOPHARMACEUTICAL COMPOSITION BASED ON IT FOR TREATING PROSTATE CANCER AND METHOD FOR PREPARING RADIOPHARMACEUTICAL COMPOSITION | 2023 |
|
RU2817970C1 |
OCTAPEPTIDE FOR PRODUCING RADIOTRACERS, RADIOTRACER BASED THEREON METHOD OF DIAGNOSING TUMOURS, EXPRESSING SOMATOSTATIN RECEPTORS | 2011 |
|
RU2457215C1 |
METHOD OF OBTAINING PSMA-TARGET COMPOUND COMPLEX BASED ON UREA Lu-PS-161 AND COMPLEX | 2023 |
|
RU2808636C1 |
PSMA-TARGET COMPOUND AND ITS COMPLEX WITH RADIONUCLIDES FOR THERANOSTICS OF TUMOR EXPRESSING PSMA | 2022 |
|
RU2803734C1 |
BOMBESIN ANALOGUE PEPTIDE ANTAGONIST CONJUGATES | 2009 |
|
RU2523531C2 |
Authors
Dates
2024-09-16—Published
2019-10-31—Filed